Arrowhead Research | ARWR - Current Assets


Arrowhead Research reported $1.67B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Ligand Pharmaceuticals USD 865.42M 33.14M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Moderna USD 5.82B 45M Jun/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Novartis USD 27.35B 744M Jun/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
TG Therapeutics USD 1.09B 456.2M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026
Xencor USD 482.85M 116.97M Mar/2026